TP53 and acute myeloid leukemia: High-risk mutations include those affecting genes involved in splicing (SRSF2, SF3B1, ZRSR2), AML-related genes (IDH1, IDH2, FLT3, and RUNX1), TP53 and JAK2. The CHRS stratified CHIP/CCUS patients into low, intermediate, and high-risk groups with certain cumulative incidences for overt hematological neoplasms.